NCT00074997View on ClinicalTrials.gov

An Efficacy and Safety Study of Autologous Cluster of Differentiation 34 (CD34+) Hematopoietic Progenitor Cells Transduced With Placebo or an Anti- Human Immunodeficiency Virus Type 1 (HIV-1) Ribozyme (OZ1) in Participants With HIV-1 Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
HIV-1
Interventions
OTHER

Placebo

Single intravenous infusion of placebo.

GENETIC

OZ1

Single intravenous infusion of OZ1.

GENETIC

CD34+ cells

Autologous CD34+ cells.

Trial Locations (1)

Unknown

Darlinghurst

All Listed Sponsors
lead

Janssen-Cilag Pty Ltd

INDUSTRY

NCT00074997 - An Efficacy and Safety Study of Autologous Cluster of Differentiation 34 (CD34+) Hematopoietic Progenitor Cells Transduced With Placebo or an Anti- Human Immunodeficiency Virus Type 1 (HIV-1) Ribozyme (OZ1) in Participants With HIV-1 Infection | Biotech Hunter | Biotech Hunter